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Abstract
To determine the frequency, risk factors and mortality of nosocomial pneumonia a prospective
study was conducted in the intensive care units. In the study period, 2402 patients were included.
The nosocomial pneumonia was defined according to the Centers for Disease Control Criteria.
Overall, 163 (6.8%) of the patients developed nosocomial pneumonia and 75.5% (n = 123) of all
patients with nosocomial pneumonia were ventilator-associated pneumonia. 163 patients who
were admitted to the intensive care unit during the same period but had no bacteriologic or
histologic evidence of pneumonia were used as a control group. The APACHE II score, coma,
hypoalbuminemia, mechanical ventilation, tracheotomy, presence of nasogastric tube were found
as independent risk factors. Crude and attributable mortality were 65% and 52.6%, respectively.
The mortality rate was five times greater in the cases (OR: 5.2; CI 95%: 3.2–8.3). The mean length
of stay in the intensive care unit and hospital in the cases were longer than controls (p < 0.0001).
Patients requiring mechanical ventilation have a high frequency of nosocomial pneumonia.
Background
Nosocomial pneumonia (NP) is the most frequent noso-
comial infection in the intensive care units (ICU). The
reported frequency varies with the definition, the type of
hospital or ICU, the population of patients, and the type
of rate calculated. In the recent studies, the incidence was
reported as 6.8–27% [1-4]. In an one day point prevalence
study in European ICUs, ICU-acquired pneumonia
accounted for 46.9% of nosocomial infections [5]. The
National Nosocomial Infections Surveillance (NNIS) sys-
tem reported that NP accounts for 31% of all nosocomial
infections in intensive care units [6]. The risk of pneumo-
nia is increased in the intubated patients receiving
mechanical ventilation (MV) and the ventilator associated
pneumonia (VAP) frequencies varied between 7–70% in
different studies [7-9]. NP developed at a rate of 0.9 cases
per 1000 patient-days in non-ventilated patients versus
rates of 20.6 cases per 1000 patient-ventilator-days and
14.8 cases per 1000 patient-days in patients who received
any MV [10]. NP is also associated with high morbidity
and mortality in ICUs. The increasing incidence of infec-
tions caused by antibiotic-resistant pathogens contributes
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to the seriousness of these infections. The mortality rate
reaches to 20–50%, and also NP caused by high-risk path-
ogens (Pseudomonas aeruginosa, Acinetobacter spp., Stenotro-
phomonas maltophilia) are associated with higher mortality
[1,11,12]. Patients with NP, stay 1 to 2 weeks longer than
those without NP and result in higher costs [13].
Studies on NP are mainly reported from the United States
and European countries, whereas studies from around the
world are missing. The aims of this study were to assess
incidence, risk factors and mortality of NP in Eurasian
intensive care units.
Methods
Between February 2001 and February 2002 a prospective
study was conducted among intensive care units (ICU)
patients of the Erciyes University Hospital. This university
hospital is a teaching hospital and full time intensivists
care the patients in ICUs. Patients from the surgical ICU
(SICU) (24 beds), medical ICU (MICU) (9 beds) and
burn unit (7 beds) were included. The SICU consist of 8
neurosurgical (NICU), 8 general surgery (GICU) and 8
cardiac surgery (CICU) beds. Patients older than 16 yr of
age were included. The same infection control doctor col-
lected data and intensivist reviewed the diagnosis of pneu-
monia. Data collection included physical examination
findings, APACHE II scores on admission, consciousness,
risk factors (intubation, MV, presence of nasogastric tube,
enteral nutrition, tracheotomy), prior surgery, immuno-
suppression, prior antimicrobial and antacid or histamine
type 2 (H2) blocker therapy, clinical outcome, length of
stay in ICU and in the hospital.
163 patients who were admitted to the ICU during the
same period but had no bacteriologic or histologic evi-
dence of pneumonia were used as a control group.
In the ICUs infection control doctor collects active surveil-
lance data routinely and empiric antibiotic therapy is
directed at the most prevalent and virulent pathogens
reported in these data. Appropriate antibiotic therapy
included the administration of at least one antibiotic with
in vitro activity against the bacterial pathogens isolated
from the patient's respiratory secretions, as well as from
blood and pleural fluid when applicable [14].
NP was considered when new and persistent (more than
48 h) pulmonary infiltrates not otherwise explained
appeared on chest radiographs. Moreover, at least two of
the following criteria were also required: 1) fever >38°C;
2) peripheral leukocyte count >10 000/mm3; 3) purulent
endotracheal secretions with a Gram stain showing one or
more types of bacteria [15]. VAP was considered when its
onset occurred after 48 h of MV and was judged not to
have been incubated before starting MV [16]. Admission
APACHE II score was used to determine the severity of the
illness, and attributable mortality was registered, as were
laboratory values, electrocardiogram, x-ray, and arterial
blood gas values.
Extra length of stay was calculated comparing the extra
stay after onset of pneumonia in the cases and after a ref-
erence date (the mean value of the extra stay after onset of
pneumonia in the cases) in the control group.
Microbiology
Giemsa stains of sputum samples were performed for all
patients. Sputum samples, containing more than 25 poli-
morphonuclear leukocyte (pnl) and less than 10 (×100)
epithel were classified as purulent. If necessary, samples
were obtained by nasotracheal aspiration. In that case,
samples containing more than 10 pnl (×1000) were
defined as purulent. Quantitative cultures of all purulent
samples were performed using standard methods. Suscep-
tibility testing was performed by disc diffusion method. In
the absence of an alternative diagnosis a bronchoalveolar
lavage was performed. In some case, pleural fluid was
obtained by thoracentesis and examined for cell count,
smear, Gram- and Giemsa-staining and microbiological
culture.
Statistical Analysis
All data were evaluated using SPSS. Parameters were com-
pared using univariate and multivariate logistic regression
and chi-square tests. Student t test was used to compare
the extra length of stay. Data were given as mean ± SD and
a p-value of <0.05 was accepted as significant.
Results
During the study period, 2402 patients were admitted to
the ICUs. Distribution of patients by ICU and length of
stay in the ICU are shown in table 1. Overall, 163 (6.8%)
of the 2402 patients developed NP; 105 (5.8%) SICU- and
58 (11.7%) MICU-patients. The demographics of the NP
patients and control group are shown in table 2. The per-
centage of NP in NICU, GICU and CICU were 7.8%, 6.3%
and 1.2%, respectively. During the study period no burn
unit patient developed NP. The incidence of NP in MICU-
patients was much higher than in SICU-patients (X2 =
19.7, p < 0.0001). Length of stay in the MICU was signif-
icantly higher than in the SICU, 21.3 ± 21.4 versus 16.2 ±
8.8 days, respectively (p < 0.05). Characteristics of
patients who developed NP are shown in table 3.
Overall, 17% of all patients requiring MV (n-724) devel-
oped VAP. Thereby, VAP accounts for 75.5% (n = 123) of
all patients with NP (n = 163) during the study period
(OR: 5,4; 95% CI: 3,36–8,75; p < 0,001) (Table 4).
Mechanical ventilation was more frequently used in
MICU patients than SICU patients (X2 = 6.6, p < 0.01).Annals of Clinical Microbiology and Antimicrobials 2004, 3:17 http://www.ann-clinmicrob.com/content/3/1/17
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Table I: Numbers of patients and length of stay in ICU
ICU No. of beds Total patient (n) Total length of stay (d) Mean length of stay (d)
SICU 24 1806 5594 3.1
NICU 8 767 2213 2.9
GICU 8 636 2132 3.4
CICU 8 403 1249 3.1
MICU 9 495 2086 4.2
Burn Unit 7 111 1765 15.9
Total 40 2402 9445 3.9
Table II: Demographic Factors of Study Patients*
NP patients (n = 163) Control (n = 163) t p
Age 53.30 ± 16.05 51.50 ± 16.87 0,985 >0,05
Admission APACHE II 10.86 ± 3.42 10.18 ± 4.56 1,526 >0,05
Gender 0,454 >0,05
Male 98 (60) 102 (63)
Female 65 (40) 61 (37)
Diabetes mellitus 22 (14) 32 (20) 1,49 >0,05
COPD 36 (22) 11 (7) 4,027 <0.001
Cardiovascular disease 31 (19) 19 (12) 1,848 >0,05
Uremia 36 (22) 12 (7) 3,823 <0.001
Neoplasia 29 (18) 17 (10) 1,914 >0,05
Immunosuppressive therapy 6 (4) 3 (2) 1,013 >0,05
Coma 143 (88) 23 (14) 19,58 <0,001
Trauma 35 (22) 85 (52) 6,038 <0,001
* Data presented as mean ± SD or No. (%)
Table III: Characteristics of patients
Characteristics MICU NICU GICU CICU Total
Age (mean ± SD) 52.9 ± 15.1 50.25 ± 17.57 58.28 ± 14.38 55.00 ± 14.68 53.3 ± 16.1
Admission APACHE II, (mean ± SD) 11.2 ± 3.3 10.43 ± 3.12 11.03 ± 3.67 11.20 ± 6.38 10.9 ± 3.4
NP APACHEII, (mean ± SD) 16.2 ± 5.1 14.73 ± 3.94 16.30 ± 4.79 14.80 ± 6.37 15.6 ± 4.7
Length of stay in ICU (d, mean ± SD) 21.3 ± 21.4 14.42 ± 8.87 19.47 ± 8.20 12.20 ± 3.96 18.0 ± 14.7
Length of hosp. stay (d, mean ± SD) 25.0 ± 22.5 21.60 ± 11.93 24.78 ± 12.13 18.40 ± 8.26 23.5 ± 16.4
Table IV: Rate of VAP in ICUs
ICU No. of patients required MV No. of patients with VAP (%)
SICU 550 72 (13.1)
NICU 141 38 (27.0)
GICU 157 31 (19.7)
CICU 252 3 (1.2)
MICU 163 51 (31.3)
Burn unit 11 0 (0)
Total 724 123 (17.0)Annals of Clinical Microbiology and Antimicrobials 2004, 3:17 http://www.ann-clinmicrob.com/content/3/1/17
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Consequently, the incidence of VAP was higher for MICU-
than SICU-patients (X2 = 29.2, p < 0.0001). Furthermore,
the length of ventilation was higher for patients admitted
to MICU (6.3 ± 4.0) than SICU (5.1 ± 3.7), but the differ-
ence was not statistically significant.
During the study period patients received 3128 ventila-
tion days, with an average duration of 11.3 ± 10.0 days per
ventilated patient. The device-related incidence rate for
VAP was 39.3/1000 ventilation days. The incidence per
1000 ventilation days was 41.9 in SICU, 36.6 in MICU,
66.0 in NICU, 38.0 in GICU, and 9.1 in CICU patients.
The mean onset day of NP after MV was 4.2 ± 3.9 days.
Univariate analysis suggested the following risk factors for
the development of NP: the APACHE II score, coma,
COPD, uremia, hypoalbuminemia, MV, tracheotomy,
enteral feeding, presence of nasogastric tube and previous
treatment with broad-spectrum antibiotic (Table 5). How-
ever, multivariate logistic regression showed that the
APACHE II score (OR: 1.23; 95% CI: 1.13–1.33), coma
(OR: 2.83; 95% CI: 1.24–6.47), hypoalbuminemia (OR:
2.23; 95% CI: 1.01–4.93), MV (OR: 3.35; 95% CI: 1.71–
6.56), tracheotomy (OR: 6.03; 95% CI: 1.36–26.76) and
presence of nasogastric tube (OR: 2.68; 95% CI: 1.33–
5.41) were significant independent predictive factors for
the development of NP.
187 pneumonia episodes were observed during the study
period, resulting in the isolation of 257 microorganisms.
The most commonly isolated pathogens were Gram-neg-
ative bacteria (85.6%). Among these pathogens, A. bau-
mannii  (29.6%),  P. aeruginosa (20.6%),  Klebsiella
pneumoniae (14.4%) were the most common.
Empiric antibiotic therapy was based on previous surveil-
lance cultures and the Gram stain results. Therapy was
adjusted according to the reports of susceptibility testing.
Crude and attributable mortality were 65% and 52.6%,
respectively. The mortality in patients without NP was
26.4% (Table 6). The risk of death was five times higher
for patients with NP (OR: 5.2; 95% CI: 3.2–8.3; p <
0,001). The mortality rates were high in high risk patho-
gens (Table 7). The appropriateness of the empiric therapy
did not contribute to increased mortality (Table 8).
The mean length of stay in the ICU and hospital for the
patients with NP were 18.04 ± 14.74 days and 23.49 ±
16.44 days, respectively. The mean length of stay in the
ICU and hospital for the control group 3.10 ± 3.03 and
9.64 ± 5.08 days, respectively. This difference was statisti-
cally significant (p < 0.0001). The extra stay in the control
group was 4.36 ± 3.87 and 17.04 ± 14.17 in the patients
(p < 0.001).
Discussion
The incidence of NP was reported different in different
studies, which may be justified by the presence of differ-
ent populations with variable ages, underlying diseases,
and other associated risk factors. Incidence ranges from
6.8 to 27% [1-4] and also in this study it was 6.8%. Devel-
opment of NP varies according to the different type of
ICUs. Craven et al. [17] reported that the rate of pneumo-
nia was higher in MICU but the difference was not signif-
icant. In the present study, the rate of NP and VAP was
significantly higher in MICU than SICU, possible due to
the differences in the proportion of patients that needed
MV and the duration of MV.
MV increases the risk of NP by 3- to 10-fold [1,18-23],
resulting in an VAP incidence of 7 to 70% [7-9]. Gener-
ally, the duration of mechanical ventilation increases the
risk of pneumonia. Cook et al. [24] reported that the rate
of VAP increased 3% per day in the first week of
ventilation, 2% per day in the second week, and 1% per
day in the third week. In this study, 75.5% of the cases
with NP occurred in ventilated patients. From 724
patients who required MV 123 (17%) developed VAP.
Accordingly, patients on MV had a 3-fold higher risk to
develop NP than the non-ventilated patients.
Consequently, the use of non-invasive MV should be pre-
ferred whenever possible, since it has lower rates of noso-
comial infections [25-27].
Coma was described as another important risk factor for
NP. In these patients, local defense mechanisms of the res-
piratory airway are altered, allowing microorganisms to
better attach to and colonize the mucosal surface. Further-
more, depression of the level of consciousness signifi-
cantly increases the chance of aspiration, and as a result
development of NP [3,28]. In our study, comatose
patients had a 2-fold increased risk of NP.
The causative agents of NP differ by the study population
and diagnostic techniques but generally Gram-negative
bacteria are the most common ones [3,4,28-33]. Coloni-
zation of the oropharynx, trachea or stomach with Gram-
negative pathogens has been identified as a risk factor for
NP [15,31]. Also in our study, the most common patho-
gens were Gram-negative bacteria. Furthermore, prior
antibiotic therapy and COPD, leading to colonization
with Gram-negative aerobic pathogens, were reported to
be risk factors for the development of NP [11,28,30,34].
In our patient population, univariate analysis suggested
that previous antibiotic treatment and COPD increased
the risk of pneumonia, but interestingly they were not
independent risk factors in multivariate analysis. Further-
more, the presence of a naso-gastric tube was found to be
a risk factor in our study population. Naso-gastric tubes
impair the function of the gastroesophageal sphincter andAnnals of Clinical Microbiology and Antimicrobials 2004, 3:17 http://www.ann-clinmicrob.com/content/3/1/17
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Table V: Results of univariate analysis of potential risk factors for NP
Risk Factors OR 95% Confidence Interval p
Age 1.0 0.99 – 1.02 ns
APACHE II 1.3 1.22 – 1.38 <0.001
Coma 6.6 3.75 – 11.48 <0.001
Trauma 1.7 0.93 – 2.97 ns
COPD 3.9 1.91 – 8.01 <0.001
Diabetes mellitus 0.6 0.35 – 1.16 ns
Central nervous system disorder 1.1 0.71 – 1.77 ns
Uremia 3.6 1.78–7.14 <0.001
Hypoalbuminemia 3.3 1.99–5.61 <0.001
Mechanical ventilation 5.4 3.36–8.75 <0.001
Tracheotomy 12.5 3.75–41.89 <0.001
Enteral feeding 13.9 6.38–30.13 <0.001
Presence of nasogastric 6.3 3.89–10.18 <0.001
Previous antibiotic treatment 3.3 1.94–5.62 <0.001
Immunosupressive therapy 2.0 0.50–8.29 ns
Antacids or H2 antagonist therapy 0.6 0.25–1.36 ns
Thoracoabdominal surgery 1.0 0.63–1.69 ns
ns: non-significant
Table VI: Comparisons of outcomes between NP and control group
NP group n (%) Control group n (%) X2 p
Mortality 106 (65.0) 43 (26.4) 47.5 <0.0001
Improve 57 (35.0) 120 (73.6)
Attributable mortality 52.6%
Table VII: Mortality rates in high risk pathogens
Microorganism Mortality/Total (%)
Gram negative 61/97 (62.9)
A. baumannii 31/42 (73.8)
P. aeruginosa 19/28 (67.9)
Gram positive 10/15 (66.7)
MRSA 10/14 (71.4)
Table VIII: Appropriateness of empiric therapy and mortality
Appropriate n (%) Inappropriate n (%) X2 p
Survive 43/121 (35.5) 14/42 (33.3) 0.005 >0.05
Death 78/121 (64.5) 28/42 (66.7)Annals of Clinical Microbiology and Antimicrobials 2004, 3:17 http://www.ann-clinmicrob.com/content/3/1/17
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increase the risk of maxillary sinusitis, oropharyngeal col-
onization and reflux, all of which may lead to migration
of bacteria [35]. Accurate evaluation of nutritional status
and early initiation of enteral feeding is important in ICUs
patients and can aid to preserve the gastrointestinal epi-
thelium and prevent bacterial colonization. However, it
may also increase the risk of gastric distention, coloniza-
tion, aspiration, and pneumonia. Though, to reduce the
risk of NP, it is important to avoid unnecessary enteral
nutrition [30]. In univariate analysis, we found enteral
feeding as a risk factor, but in multivariate analysis it was
not an independent risk factor. For a long time it was
assumed that increased gastric pH levels e.g. after the use
of antacids, would allow Gram-negative microorganisms
to multiply in the stomach, and consequently lead to an
increased rate of NP. Our study results confirm what was
reported by George et al. [36], namely that the use antac-
ids or H2 antagonists did not increase the risk of NP.
In the literature, tracheotomy is described as a significant
risk factor for NP. Bronchial colonization during the pro-
cedure and (prolonged) continuation of sedation after the
procedure will furthermore increase the occurrence of NP
[28], a fact that was also seen in our patients. Patients with
tracheotomy had a 7-fold increased risk of NP.
The role of advanced age and high APACHE II scores as
risk factors of NP are still under discussion. While Kollef
et al. [37] report them as significant risk factors, earlier
investigations do not support this [1,30]. In our present
study, the APACHE II score was a significant risk factor for
the development of NP; suggested that the severity of the
general condition of the patient was important. Besides,
uremia was found as a risk factor in univariate analysis.
Patients with NP have a significantly higher morbidity
and mortality [12,35,38]. Heyland et al. [38] reported the
crude mortality rate of VAP 23.7% and an attributable
mortality rate 32.3%. However, numerous studies have
demonstrated that severe underlying illness predisposes
patients in the ICU to the development of pneumonia,
and their mortality rates are, as a result, high. Survival in
patients with NP primarily by the degree of severity of ill-
ness at the time of diagnosis [23,39,40]. On the other
hand, this does not exclude the possibility that certain
subgroups of patients, such as patients with VAP caused
by antibiotic resistant bacteria may have had extra attrib-
utable mortality rate [1]. In our study, the crude mortality
rates for cases and controls were 65.0% and 26.4%,
respectively and the mortality rates were highest in high
risk pathogens. The mortality rate was five times greater in
cases and attributable mortality of NP was 52.6%. Recent
clinical investigations suggest that patients receiving inap-
propriate initial therapy have a greater mortality rate com-
pared to patients receiving antibiotics to which the
isolated bacteria were sensitive. However, in this study
there was no statistically difference between the mortality
rates of the patients who received appropriate and inap-
propriate initial therapy.
As a result of the increased morbidity, patients with VAP
remain hospitalized for 4–17 days longer than controls
[35-38]. This observation was confirmed in the present
study. The incidence of NP and VAP in MICU were signif-
icantly higher than in SICU patients and consequently the
length of stay in the MICU was significantly higher than
in the SICU.
In conclusion, NP is a major cause of morbidity and mor-
tality in ICU patients. Especially patients on mechanical
ventilation are at high risk. Studies determining the
impact of "old" and "new" risk factors of NP should
repeatedly be performed in order to effectively guide the
implementation of preventive measures methods.
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